Brief: Urogen Pharma Reports Highest Revenue Quarter And Recent Corporate Developments

UroGen Pharma

16/03/2023 12:42

March 16 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA REPORTS HIGHEST REVENUE QUARTER AND
SIGNIFICANT
FULL YEAR 2022 GROWTH AND RECENT CORPORATE DEVELOPMENTS
    * Q4 LOSS PER SHARE $1.22
    * AS OF DECEMBER 31, 2022, CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES TOTALED APPROXIMATELY $100 MILLION
    * ANTICIPATES FULL YEAR 2023 NET PRODUCT REVENUES FROM
JELMYTO TO
BE IN THE RANGE OF $76 TO $86 MILLION
    * ANTICIPATES FULL YEAR 2023 OPERATING EXPENSES IN THE RANGE
OF
$135 TO $145 MILLION
    * QTRLY LOSS PER SHARE $1.22
    * QTRLY REVENUE $18.1 MILLION VERSUS $16.2 MILLION
    * Q4 EARNINGS PER SHARE VIEW $-1.07, REVENUE VIEW $18.5
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nBw5gMJc9a 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))